Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Endovascular Today4d
Arsenal’s EMBO-02 Study of NeoCast for cSDH Treatment Enrolls Initial Cohort
Arsenal Medical announced the completion of the initial cohort enrollment in the EMBO-02 clinical study of the company’s ...
Equillium announces itolizumab study achieves secondary endpoint
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
Endovascular Today6d
Akura Begins Pivotal Trial of Katana Thrombectomy System in Pulmonary Embolism
Akura Medical, Inc., a privately held portfolio company of Shifamed LLC that is developing treatments for venous thromboembolis ...